Irbesartan, Ciprofibrate and Their Combination Onto the Endothelial Functions
Status:
Completed
Trial end date:
2007-08-01
Target enrollment:
Participant gender:
Summary
The rationale of the study is to clarify whether the supplementation of irbesartan with
ciprofibrate could increase the antihypertensive effect, could improve the endothelial
functions, and/or could affect the atherogenic small-dense LDL-, oxydized LDL concentrations,
onto the paraoxinase activity and on the CRP and insulin levels.